Directory · KR
Biotechnology Research in South Korea
A register of firms and the professionals working at them in the Biotechnology Research sector based in South Korea. Browse the public index, then filter or export on Kipplo.
Companies
299 on file
3billion
3billion is dedicated to making rare disease diagnosis faster, more accurate, and accessible for patients everywhere. We provide AI-driven genetic testing covering all rare diseases, helping physicians deliver answers with confidence. Through our unique daily reanalysis system, patients continue to receive new diagnoses without additional cost. patients in 80+ countries have already been tested, in collaboration with 800+ medical institutions worldwide. In 2024, 3billion was listed on KOSDAQ, a recognition of our leading technology and global growth. Our mission is simple yet powerful: to ensure that every rare disease patient has a chance to receive an answer. For inquiries: support@3billion.io
51 to 200 staff
Easy Bio, Inc
Easy Bio, Inc. is an animal nutrition company based out of South Korea.
51 to 200 staff
Noul Co., Ltd
Noul Inc. has developed the next generation POC (Point-Of-Care) blood testing platform for resource-limited medical facilities, clinics, and local hospitals. Noul seeks to solve global challenges that threaten human life, to discover novel solutions, and to establish a new gold standard in POC blood testing. Noul’s solution aims to improve accessibility to proper health care by integrating innovations in biology, artificial intelligence, mobile technology, robotics, and software/hardware engineering. Noul has filed over 65 global patents, conducted more than seven field clinical trials, and has research partnerships with world-class global institutions.[Mission] We explore global challenges that threaten human health and life, discover novel potential solutions, and realize those possibilities.[Goal] 1. To contribute to eliminating malaria, tb, aids and other neglected diseases through innovative diagnostic platform. To proactively increase healthcare accessibility through next-generation blood diagnostics platform.
51 to 200 staff
Sartorius
Sartorius is a leading international partner of life sciences research and biopharmaceutical manufacturing. We help our customers simplify progress from drug discovery to manufacturing so that more people can have access to better medicine. With this, we are part of the solution in the fight against diseases worldwide. With innovative laboratory instruments and consumables, the Lab Products & Services division focuses on laboratories performing research and quality control at pharmaceutical and biopharmaceutical companies as well as academic research institutes. The Bioprocess Solutions division, with its broad product portfolio focusing on single-use solutions, helps customers manufacture biotech medications, vaccines, and cell and gene therapies safely, rapidly, and economically. Based in Göttingen, Germany, Sartorius also has a strong global reach with more than 60 production and sales sites worldwide. We regularly expand our portfolio through the acquisition of complementary technologies. In 2024, Sartorius generated sales revenue of around 3.4 billion euros. Currently, more than 13,500 employees from around 110 nations are working for customers around the globe. Join our team, partner or collaborate with us.
10001+ staff
Abl Bio Inc
ABL Bio Inc.(Kosdaq: 298380) is a South Korean biotechnology company dedicated to the development of bispecific antibody therapeutics to improve and save people's lives. With our BsAb platforms ‘Grabody-T,’ ‘Grabody-I’ and ‘Grabody-B,’ we have built a robust pipeline of multiple clinical and pre-clinical stage drug candidates. In the oncology area, we have developed Grabody-T, a modular 4-1BB engaging platform that has demonstrated excellent efficacy and safety. We also created a next-generation antibody drug conjugate program to treat various cancers. In the neurodegenerative disorder space, we have developed Grabody-B platform, which is designed to maximize blood-brain barrier penetration. Grabody-B is applicable to various CNS targets across a plethora of neurological disorders, potentially providing a breakthrough to address the high unmet medical needs in neurodegeneration. We continue to actively expand and advance our pipeline through global strategic partnerships. For more information, please visit http://ablbio.com
51 to 200 staff
Dna Link
A frontier company in medical genetics research DNA Link is currently in collaboration with Korea’s most renowned clinical research specialists studying genetic effects of various diseases including diabetes, cardiovascular disease, cancer, atopy, and digestive diseases. Recent advancements in genomic research technology have enabled rapid analysis of whole genomes. Our current research projects utilize this technology to identify relationships between diseases and genomic content. In the past, genetic disease studies were conducted using a finite set of candidate genes as targets for research. While the results were valuable, the success of this approach was limited because diseases can depend on multiple factors, genetic and environmental. Modern genetic research methodologies take a more extended approach, considering the entire human genome to search for potential disease markers. In addition to identifying disease-related genes, DNA Link is working to develop disease diagnostic systems as well as personalized treatment methods. Using DNA Chip and Next Generation Sequencing technologies, we are currently developing cancer diagnostic systems by identifying common variants in DNA copy numbers for various cancers including lung cancer and breast cancer
51 to 200 staff
Edgc Eone-Diagnomics Genome Center
Global NGS Company, EDGC We provide the value for a healthy lifestyle by suggesting customized healthcare based on genome information. Through genome analysis, we have provided genetic screening tests to help people predict cancer and diseases and to offer personalized healthcare. We have developed cutting-edge technology for genome analysis through constant research and development and have established business networks to expand its influence on the global market. EDGC will become the company creating a healthy and happy life and a better future for all.
51 to 200 staff
Toolgen Inc
Toolgen is committed to conducting research for revamping genome editing technology and thus developing not only therapeutics for humans but plants and animals of which the genetic characters are modified by the editing.
51 to 200 staff
Bionsight
Bionsight is a drug discovery company that integrates the power of chemoproteomics and AI technologies to facilitate target identification and off-target profiling within the drug development process. We offer a chemoproteomics platform named Javelin, capable of identifying thousands of proteins, thereby enabling comprehensive protein-ligand interaction mapping on a proteome-wide scale. This state-of-the-art method provides numerous benefits for drug discovery. It empowers us to uncover multiple interactions, provides broad scope applicability to diverse targets, opens the potential to delve into the mechanisms of action and side effects, and presents a cutting-edge strategy to address previously "undruggable" targets.
11 to 50 staff
Genecast
The earlier you discover, the better you recover." Genecast is a biotechnology company specializing in cancer diagnosis using liquid biopsy. Our proprietary ADPS technology offers maximum detection sensitivity of quickly and accurately recognizing cancer mutation genes. With ADPS, we enhance treatment options, improve the success rate of targeted therapies, and enable early cancer detection. Our mission is to design a healthier 150-year life span by diagnosing previously undetectable diseases, treating the untreatable, and preventing illnesses more effectively. Our vision is to make cancer a manageable disease, contributing to a "healthier 150 years." Face cancer with ADPS. For more information, please visit our website.
11 to 50 staff
Qureator
Qureator is a pioneering AI-powered human biology platform company dedicated to revolutionizing drug discovery and development for complex diseases. Traditional drug discovery models—such as AI-driven computational predictions, animal testing, and 2D cell cultures—struggle to replicate human biology accurately, leading to high failure rates and costly inefficiencies. Qureator bridges this gap by integrating Next-Generation Microphysiological Systems (MPS) technology with cutting-edge AI-driven solutions, offering a human biology-based platform that mimics complex disease phenotypes and patient-specific responses. At the heart of Qureator’s platform are two groundbreaking technologies: Curiochips and Quricore. Curiochips integrates patient-derived cells into physiologically relevant, high-throughput models, allowing for more accurate disease replication and drug testing. Quricore, an AI-powered analytical engine, accelerates research by enabling rapid, high-precision hypothesis generation and data-driven decision-making. By leveraging advanced computational modeling and predictive analytics, Quricore enhances explainability and ensures robust insights, providing greater visibility into drug efficacy and toxicity for those driving advancements in drug discovery. This approach significantly reduces time and cost associated with traditional preclinical testing.
11 to 50 staff
Voronoi
VORONOI, a leading biotech in South Korea EGFR-Exon20Ins Lisenced out to ORIC Parmaceuticals in 2020 RET-Fusion Lisenced out to Inno.N in 2021 Anticipated upcoming IPO on KOSDAQ for 4Q, 2021
51 to 200 staff
Gc Cell
GC Cell stands at the forefront of cell therapy innovation with fully-integrated capability from research to commercialization. Offering customized solutions tailored to partners` needs, We provide end-to-end full value chain CDMO and bio logistics service. Our mission is to fast-track the innovation in cell and gene therapies, aiming to enhance the clinical outcomes of each and every patient, shaping the future of healthcare.
501 to 1000 staff
Proteina
PROTEINA has developed a first-in-class protein-protein interaction (PPI) analysis platform using proprietary 'single-molecule co-immunoprecipitation' technology. Our platform enables quantitative PPI measurements at the single-molecule level, delivering analyses with unparalleled accuracy and speed. PROTEINA has accumulated extensive know-how in developing assays measuring targeted PPIs as well as the analytic capability to model the efficacy of a drug based on its PPI metrics. Our mission is to revolutionize protein analysis; developing effective, new approaches to diagnosing diseases and discovering new drug candidates using our novel technology. For more information regarding PROTEINA, please visit us at
51 to 200 staff
Trial Informatics
We are Trial Informatics (TI), a Data Science company founded by a group of experienced medical doctors, health scientists, IT professionals, and data scientists in South Korea with the vision to reinvent clinical trial data with digital health technologies. Our mission is to digitalize clinical trial processes by capitalizing on Data Science, thereby supporting medical doctors, clinical researchers, contract research organizations (CROs), pharmaceutical companies, and other stakeholders to succeed in a clinical trial, small or large, with the state-of-art IT technologies and Data Science tools at every important stage of clinical development. Our solutions aim, among others, to streamline clinical research process, integrate data workflows of various stages, warehouse clinical trial data in a standardized manner, uncover new insights from past data, and serve as a digital platform for Decentralized Clinical Trials (DCTs). We have two child companies, TI Image and iAID. TI Image (https://tiimage.com), headquartered in Singapore and led by Dr. Amy Lee, is a global imaging CRO providing, most importantly, the central reading service for imaging clinical trials end-to-end on all the major therapeutic areas. iAID (https://iaidimage.com), headquartered in South Korea and led by Dr. Jeongjin Lee, is an AI company specializing in the AI medical imaging process, with invention of a high-speed web-PACS, which is now widely employed by the leading hospitals and medical research labs in South Korea. Contact: cs@trialinformatics.com
11 to 50 staff
Lg Chem Life Sciences Usa, Inc
At LG Chem Life Sciences USA, we aim to transform lives by inspiring science and leading innovation in the key therapeutic areas of Immunology, Oncology, and Metabolic diseases. Formerly LG Chem Life Sciences Innovation Center, LG Chem Life Sciences USA, located in Boston, MA, is the United States hub of LG Chem Life Sciences Company for global investment, development, and open innovation. Through our R&D pipeline and together with key strategic partners, we plan to bring disruptive technologies, new drugs, and digital healthcare forward.
51 to 200 staff
Pico Entech Co Ltd
PICO Entech (Enzyme Technology) is a unique bio-tech company founded in South Korea in 2014. We focus R&D for ALDH (Aldehyde Dehydrogenase) enzyme and related diseases arising from its deficiency. We've commercialized the ARC, ALDH Related Compounds, which we produce by performing special fermentation techniques with patent cocktailed microbes for the first time in the world. For its application products are the hangover treatment called 'KISLip', health supplements and more. You can find more information on our websites below,
11 to 50 staff
Sewon Cellontech Co., Ltd
Sewon Cellontech (listed on Korean Stock Market, KOSPI) is a leading korean bio-technology company producing regeneration medicine and medical devices, native collagen, and skin care product. We have developed and provided advanced cell therapy products for cartilage and bone regeneration, and we also supplied various collagen products. It has been marketing the skin care products, NovoSstrata and NovoFill, over the world. Since SEWON CELLONTECH has developed the patented collagen manufacturing, it has been dedicated to serving discerning customers fine formulation for skin with the specialized collagen. The collagen used for NOVOSTRATA and NovoFill is not a general collagen in the market but atelocollagen which is well-known as 100% genuine native collagen while others are structurally changed by extreme conditions. Based on the characteristics of the NovoStrata and NovoFill containing the atelocollagen, it gives much beneficial effects to skin regeneration and anti-aging actions. Moreover, the atelocollagen for cosmetics use is also available from us (Brand : RMS BioCollagen ) which could be better option for raw-materials of cosmetics. The atelocollagen has been listed on the INCI of USA PCPC(Personal Care Products Council).
501 to 1000 staff
Shaperon
Shaperon is a clinical stage biotech company developing novel inflammasome inhibitors(small molecule). Its unique mechanism of action of GPCR-regulated P2X7 inhibition suppresses a broad spectrum of inflammatory cytokines including IL-1β, IL-18, IL-6, and TNF-α, etc. by controlling both priming and activation phase of inflammasome, whereas conventional approaches are designed to suppress only the activation phase. With this unique and novel modality which is best suited to address complex immune-mediated inflammatory disorders, we are currently developing multiple clinical programs in atopic dermatitis, cytokine release syndrome, Alzheimer’s disease, ulcerative colitis, NASH, etc. In addition to inflammasome R&D programs, Shaperon has anti-viral, anti-cancer nanobody therapeutics. Shaperon’s proprietary immunized nanobody libraries combined with high throughput screening and in vitro/in vivo system enable us to fast forward the realization of advantages of Nanobodies over conventional antibody-based medicines. We currently developing multi-valent, multi-specific Nanobodies in multiple delivery forms in oncology and viral infection diseases.
11 to 50 staff
Theragen Bio
Global genome service provider and Platform-based biopharmaceutical company.
51 to 200 staff
Acebiome
AceBiome is one of South Korea’s fastest-growing microbiome innovators, specializing in science-driven probiotics for weight management and gut health, and expanding into natural solutions for joint health, bone support, and skin function. With deep expertise in microbiome science, AceBiome is best known for its proprietary strain Lactobacillus gasseri BNR17®, the first probiotic approved by Korea’s MFDS for body fat reduction. Its consumer brand BNRThin continues to lead the weight care category, particularly as a companion probiotic to GLP-1 therapies. Beyond digestive health, we’re expanding into healthy aging and life-cycle wellness with AnaParactin™, a plant-based joint and bone health line featuring clinically studied ParActin® (Andrographis paniculata) and Etnacare™, a beauty-from-within skin health support powered by Red Orange Complex H (ROCH). At AceBiome, we are committed to shaping the future of sustainable, holistic wellness with clinically proven solutions for both individuals and future generations.
51 to 200 staff
Amyloid Solution Inc
Erasing Alzheimer's Disease” is the mission of Amyloid Solution and the reason we exist. To erase the disorder, our R&D focuses on everything of Alzheimer’s disease. We search for fundamental culprits, interpret their systemic interactions, and discover methods for varied patient cases. Based on in-depth understanding of the disorder, we aim to discover and provide effective, safe, and diverse therapeutic solutions to overcome Alzheimer's disease. We are currently in international and domestic collaboration with key scientists and biopharma industries by open innovation and we are honored to receive proposals and invitations by future collaborations. We, Amyloid Solution, promise you that we will become a valuable and wise platform leading and supporting the challenge of Alzheimer drug discovery.
11 to 50 staff
Cj Bioscience
CJ Bioscience Global No.1 Microbiome Company CJ Bioscience is pioneering development of next-generation biopharmaceuticals for microbiome health with its leading edge in the field of ‘Wellness’. We aim to provide healthcare solutions for unmet medical needs by examining the relationships between human microbiomes and various diseases. In addition, CJ Bioscience, which uses leading world-class bioinformatic analysis technology, will discover promising candidates that can be used in the treatment of incurable diseases, and accelerate the development of new drugs utilizing our ‘Ez-Mx™ Platform’ to become the global No. 1 microbiome company. Microbiome We plan to enter clinical trials (Phase 1) of a new drug development pipeline for treatment of immuno-oncology, autoimmune, and CNS (Central Nervous System) diseases and to promote technology export through joint research with Big Pharma. Also, we are constructing a ‘Ez-Mx™ Platform’ by expanding on cohort studies (comparative disease research) and securing global microbiome big data. The next generation of genomic analysis We plan to expand our business area from next generation sequencing (NGS)-based microbiome genomic analysis to microbial infection diagnosis. We will further upgrade our state-of-the-art NGS and bioinformatics (BI) total solution services. We are expanding the global business capabilities of EzBioCloud, a global standard bioinformatic analysis service made for researchers combining a curated microbiome database and artificial intelligence (AI) technology, and TrueBacID, the world's first genome-based infection diagnosis service. In addition, through the global launch of Gut Inside, an intestinal.
51 to 200 staff
Cubebio
CUBEBIO is a cancer specialized company contributing to human health promotion through early diagnosis of cancer. Through our unique technology and product development, we have been firmly establishing our competitive advantages to become the world’s leading company in the global cancer market. CUBEBIO’s mission is to transform the cancer diagnostic market paradigm. We are aiming to lead the global popularization of cancer self-diagnostic devices that are both accurate, fast, and easy-to-use for customers. We will strive to promote people’s health and happiness and thus become the company that our customers adore. For more information, please visit our website.
11 to 50 staff
Genoplan
Genoplan, a startup specializing in DNA testing, analyzes user’s saliva to conduct genetic analysis and give life style advice tailored for each user, including diet, health food, work-out, and cosmetics. The company was incorporated in 2014, and has operations at Seoul, Korea and Fukuoka and Tokyo, Japan. AI.
11 to 50 staff
Neuracle Science
Over the past decades, focusing on a battery of conventional genes/proteins involved in the neurodegeneration has been disappointing in the field of neurodegenerative therapeutics. With the scientific responsibility and integrity, Neuracle Science is a clinical stage biotech company specialized in the development of breakthrough therapies for those who are living with serious and devastating neurodegenerative diseases. We provide a foundation for disease-modifying treatments for neurodegenerative diseases, discovering a completely novel and invaluable gene/protein target with unknown significance using non-biased study. Neuracle Science is based in Seoul, South Korea. We were founded in 2015 by scientific leaders in neuroscience, bioinformatics-based drug discovery, GPCR-mediated signaling, and antibody drug.
11 to 50 staff
Optolane Technologies Inc
Optolane is an innovator in the healthcare and diagnosis industry, developing a POCT molecular and immunoassay diagnostic platform embedded in a bio application-specific CMOS sensor device. We offer a sophisticated diagnostic platform to the disease diagnosis and preventive home healthcare market. Our new diagnosis systems are small but simple, fast and smart.
51 to 200 staff
Portrai Inc
The Solutionist of Pharmaceutical industry Portrai leverages spatial transcriptomics to accelerate the drug discovery and biomarker discovery process. We co-develop the drugs with co-license and provide Platform-as-a-service to pharmaceuticals and biotechs. Radioligand therapy and Antibody-drug conjugate in oncology and brain diseases are therapeutic modalities of interest. AI pathology combined with spatial transcriptomics is our novel approach to make a scalable solution for companion diagnostics. 🟣 PortraiTARGET: Find the target locations that show the best distribution in the tissue and prioritize the target to develop. 🟣 PortraiDRUG & PortraiMIX: Visualize and quantify the drug distribution within the tissue slide to investigate the drug really goes to the target location well. It can be used for drug optimization and drug licensing deals. 🟣 PortraiMOA: Shows the overall changes of RNA expression comparing the spatial transcriptomics data between control and treated group to find out whether the drug works well in that location. 🟣 PortraiTME: Show biomarker distribution in the patient tissues to select the right patients for the drug by integrating H&E slide image and spatial transcriptomics data. It can predict immune/stromal cell proportions and spatial distribution from H&E slide with decent correlation, and even more it could be scaled up to other various biomarkers.
11 to 50 staff
Prazer Therapeutics
Prazer Therapeutics is a biotechnology company pioneering innovative therapeutics for various intractable diseases using rational drug design and next-generation targeted protein degradation (TPD) platform called SPiDEM. Our SPiDEM-based drug candidates for neurodegenerative diseases, cancers and inflammatory diseases have demonstrated superior pharmacokinetics and efficacy as well as reduced drug resistance compared to currently available TPD technologies. Our pipeline also encompasses anti-viral therapeutics to treat chronic hepatitis B (CHB) caused by hepatitis B virus (HBV) as well as acute lung inflammation caused by coronaviruses, influenza viruses and respiratory syncytial virus (RSV).
11 to 50 staff
Biorchestra Co., Ltd
BIORCHESTRA is an innovative biotech company focusing on research and development of ribonucleic acid (RNA) based therapeutics. Our goal is to change the therapeutic paradigm from treating the symptoms to providing fundamental cure of the diseases. As we are making steady progress in the clinical development, we seek global partners to collaborate in the areas of research and development (R&D) and the commercialization.
51 to 200 staff
Exocobio
The First and Leading Cosmeceutical/Biopharmaceutical Company based on Exosomes EXOsome COsmeceuticals & BIOpharmaceuticals
51 to 200 staff
Primoris International Co., Ltd
Primoris International develops simple but high-quality of effective product as an innovative First Mover that leads the Exosome market. Completion of ‘Reverse Aging’, We carry out a variety of businesses ranging from raw materials to the medical field with the Exosome that reverses aging.[Medical Aesthetic]#P198 ExoHealer, CURESTEM; Exosome Skin Booster #P198 ExoNature; Plant Exosome Skin Booster #NXA ExoFila; Exosome Filler #ExoPLA; Microwave Plasma Device [Derma Cosmetics]#SKINPHIILIA; Cosmetical Aesthetic Exosome Cosmetics #LABOSTEM, GD11, benestem; Stem Cell Exosome Cosmetics #57N; Began Cosmetics [Heritage Ingredients]#USC1994; Human Umbilical Cord Blood Stem Cell Exosomes #ASC1994; Human Adipose Stem Cell Exosomes #PSC1994; Plant Stem Cell Exosomes Instagram; primoris.medical.official p198.official Youtube; exosomeTV [Sales Contact Point] contact@primoris.co.kr
51 to 200 staff
Rapigen, Inc
We are continually challenging ourselves to become a leading company specialized in in-vitro diagnostics and dedicated to creating value for human health innovation. Rapigen Inc. was the first to successfully commercialize rapid diagnostics using Black Gold Nanoparticles and a dual-color system. We have leveraged this innovation through successful collaborations with various international organizations, including the WHO, Bill & Melinda Gates Foundation, Global Fund, PATH, and FIND, on numerous impactful projects. We now offer around 70 products for human and veterinary use, exporting to over 52 countries worldwide. Since 2023, we have confidently expanded into the molecular diagnostics field, manufacturing and supplying a wide range of PCR reagents and developing diagnostic kits for various infectious diseases. We understand the importance of promoting healthier lives, which is why in addition to diagnostics, we are committed to providing health screening centers and food-related solutions.
201 to 500 staff
Avelos Therapeutics
Avelos Therapeutics develops next-generation targeted oncology medicines with high unmet need, to a wider range of possibilities with present and future applications, especially in the areas of cell cycle regulation, undruggable cancer targets, and DNA damage response with a primary focus on synthetic lethality.
11 to 50 staff
Biosensor Laboratories, Inc
BioSensor Laboratories, Inc, a biotech startup based in Korea, introduces an innovative TDD(Transdermal Drug Delivery) technology applicable to both fields of cosmetics and pharmaceuticals. Our technology which goes by the brand of ‘Tissue X’ has made possible a professional dermatological procedure thorough a small sized patch. Tissue X is an innovative technology in that macromolecules that couldn’t be delivered to the epidermis(inner skin) by conventional cosmetics - such as hyaluronic acid(HA) and Argireline - can be successfully and stably delivered. Also API's that could be delivered only through subcutaneous injection such as exenatide and teriparatide can now be delivered through this small sized patch. Biosensor Lab is also developing an electro-chemistry POCT(Point of Care Testing) technology that provides an effective sensor solution to pool management and food safety.
11 to 50 staff
Cj Bio Taste & Nutrition
CJ BIO seeks to take on new and bold challenges in innovative future ingredients for wellness food and beverage, nutrition solutions, and alternative and cultured protein (meat). CJ BIO will be committed to strengthening customized solutions for “nrich”, natural premium food ingredient, and accelerating proprietary specialty nutrition solution business so that it can hasten its transformation into a high-tech Total Solution Provider in Taste & Nutrition. We, CJ BIO, will continue to provide visionary solutions for human health and nature by utilizing the value added technology and market insights.
501 to 1000 staff
Ck Regeon
CK Regeon Inc. is a biotech-based company founded in October, 2016 aiming to develop First-in-Class drugs addressing unmet medical needs. The company was established on the basis of the Transnational Research Center for Protein Function Control (TRCP/ ERC), a government-supported drug development institute, which has been directed by the CEO of CK Regeon Inc, Dr. Kang-Yell Choi, for more than 10 years. The excellence of their previous R&D achievements of his laboratory was proven by several times selections of the nationally honorary awards such as “National R&D Excellence of 100” and “excellent basic research 50”. He also successfully performed major national drug development projects such as “Korea Drug Development Fund” and “National OcoVentrue”. Currently, on the basis of the previous outcomes from TRCP, CK Regeon Inc. has been performing R&D for development of drugs targeting Wnt/β-catenin pathway related with regeneration. CK Regeon Inc. especially interested in the diseases suppressed regeneration in damaged and disease status tissues by suppression of the Wnt/β-catenin signaling. CK Regeon Inc. identified cytosolic overexpression of CXXC5, a negative feedback regulator of the Wnt/β-catenin signaling, as a major disease marker for the targeting diseases not only by usage of the disease model, but also by characterization of patient tissues. The aiming drug candidates revels therapeutic effects by restorative activation of the Wnt/β-catenin signaling followed by recovery of the tissue regeneration system. The drug candidates under the development by CK Regeon Inc. selectively function to the patients who overexpressed CXXC5, but not to healthy persons maintain low level of CXXC5 especially at cytosol. The targeting diseases include obesity, diabetes, and nan-alcoholic steatohepatitis (NASH), as well as the topically applicable drugs promoting hair growth and wound healing.
11 to 50 staff
Foodyworm Inc
Foody Worm is a Korean company dedicated to promoting the happiness of animals, people, and the earth through innovative insect-based solutions. We envision a future where insects serve as a sustainable substitute for meat protein, bringing about positive environmental and health impacts. Through our relentless pursuit of this vision, we have developed groundbreaking techniques for mass automatic breeding of insects, enabling us to achieve standardization of raw materials. This ensures consistent quality and scalability in our insect-based products. At Foody Worm, we are driven by our commitment to zero-waste agricultural food circulation and the development of sustainable protein sources. By harnessing the potential of insects, we are actively working towards reducing the ecological footprint associated with traditional meat production. Join us in our mission to create a more sustainable world, one where insects play a crucial role in revolutionizing the food industry. Together, we can pave the way for a healthier and happier future.
11 to 50 staff
Proxihealthcare Inc
Founded in 2019 in Seoul, South Korea, by YoungWook Kim, Ph.D, ProxiHealthcare Inc. is at the cutting edge of biotech innovation with its patented TROMATZWAVE® technology that focuses on combating the effects of harmful biofilms on human health and the broader environment. This state-of-the-art technology, stemming from Kim's Ph.D. research at the University of Maryland, uses bioelectric microcurrent waves to disturb the metabolism and weaken the protective layer of biofilms. Under Dr. Kim's leadership, the company has filed an impressive dossier of 122 intellectual properties, offering avant-garde solutions in healthcare, automotive, and maritime applications - from medical devices to biofouling prevention. Strategically headquartered in Seoul with an advanced in-house research lab (PAIST) and a manufacturing base in Ulsan, ProxiHealthcare Inc. has grown rapidly to over 40 dedicated professionals in South Korea. In 2022, the biotech startup opened a corporate branch (ProxiHealthcare USA Inc.) in Fort Lee, New Jersey, to establish its presence on a global scale and emphasize its dedication to being a global leader at the forefront of healthcare technology.
11 to 50 staff
Solgent Co., Ltd
SOLutions for GENetic Technologies [About Company] Located in South Korea, SolGent was founded in and has been growing for over a decade based on our strong relationships with valued customers who trust in our quality products. Since our foundation, SolGent has been manufacturing important raw materials for molecular biology, such as DNA polymerase. Utilizing our expertise, SolGent launched a series of molecular diagnostic kits in 2012. Now, as well as distributing throughout the world, we are providing our kits and raw materials to diagnostic and research related institutes based in korea like the KCDC(Korea Centre for Disease Control), Korea National Institutions and Hospitals. Solgent has a well-established manufacturing center with its own research institute equipped with state-of-the-art facilities, covering in Daejeon, South Korea. All products including the molecular diagnostic kits are manufactured in house and adhere to global standards ISO9001:2008 and ISO13485:2003. Many of our diagnostic kits have received CE-IVD certification with additional products launching in late 2015 currently processing certification.[Products]- PCR enzyme - Diagnostic kit * If you want to know more about our products, visit our website: [Business Area]- Molecular Diagnostics - Research Reagents - Sequencing Analysis [Achievement & Rewards]- ISO9001:2008 - ISO13485:2003 - CE certification for molecular diagnostics * 100% QD Double check system for all products.[Additional Info]- - solgent.tradekorea.com
51 to 200 staff
Abion Inc
ABION is the Korean drug discovery company with the pioneering spirit. Established in 2007, Abion was the first Korean biopharma to advance the concept of precision oncology. The company has robust pipeline for drug candidates in preclinical stage, clinical phase 1 and phase 2 to treat lung cancers and infectious diseases and is actively seeking research and clinical partnerships. Abion Youtube channel
11 to 50 staff
Btgin Co., Ltd
BTGin Co, Ltd. has been proudly established as a Bioventure company in Daejeon, Korea for human health and happiness by developing Biotechnology with ginseng products like ginsenosides and producing new medical materials in 2002. Recently due to the strong possibility of pharmaceutical use for ginseng and ginsenosides, the world-wide trade market of ginseng is remarkably increasing and more competitive. To use the main component of ginseng for new medicine and nutraceuticals, BTGin has been developed the enzyme technology by which new ginsenosides and effective ginseng components which have been produced through the transformation of ginseng structure. BTGin is a sole company which has a specific technology to manufacture and modify more than 30 pure single ginsenosides including Rd, F1, F2, Rg3, Rg2, Rh1, Rh2, Mc, Mc1, Compound K, Y, O, aglycone PPD, PPT in a mass production. Furthermore, BTGin Co, Ltd. possesses its own technology to examine the qualities of various ginseng products. Also BTGin is manufacturing various glyco-products such as functional food and cosmetic materials by applying its high technologies. Based on the management motto “Creation of unlimited value through free competition”, BTGin will be the leader of biotechnology in the world.
11 to 50 staff
Chungwoo
Our company thinks the customer with priority. our company thinks you as the most valuable customers to us. It will finish the hazard best always. Thank you! We are the manufacturer of electro medical / beauty instruments and general distributor for medical beauty products. History 2001 Foundation of CHUNG WOO MEDICAL Co,Ltd 2002 Medical Implement Manufacturing License (No.1302) Acquired Registered Patent -ICT Increased Capital - 0.4 million(US$) Participated Medical Equipment Show in Busan, Korea 2003 Participated Medical Aesthetic Equipment Show in Seoul, Korea Acquired Designed Quality grade (KMAC) Registered Research Development Department Be awarded GOOD DESIGN (KIDP) Participated Medical Equipment Show in Busan, Korea 2004 Registered Venture Company (New Technology) Participated Medical Equipment Show in Busan, Korea 2005 Established Specialty Sales Division for Personal beauty and Skincare device Utility Model Registration od Obesity Therapy Stimulator 2006 Approved the settlement of R&D center by Korea industrial Technology Association Acquired ISO13485:2003 2007 Extend Beauty Business Division for domestic professional beauty salon & clinics Participated Medical Aesthetic Equipment Show in Seoul, Korea Participated Diet Beauty Fair 2007, Japan Participated ZDRVOOKHRANENIYE 2007 in Moscow, Russia 2008 Participated Tokyo Health Industry Show 2008, Japan Participated Medical Aesthetic Equipment Show in Seoul, Korea
11 to 50 staff
Gemvax & Kael
Since 2008, GemVax & KAEL has operated as a cutting-edge research and development company developing proprietary peptide drug, GV1001, for treatment against various cancers and neurodegenerative disease including Alzheimer's disease and Progressive Supranuclear palsy. The fundamental driving purpose of our innovative pharmaceutical research is to facilitate significant improvements to human life through the introduction of advanced medical technology and innovation rooted in advanced scientific measures. At GemVax, we take pride in our proactive approach to medical research, and our progressive peptide-drug focused advancements have played a crucial role in the incessant global battle against incurable disease.
51 to 200 staff
Genemedicine
GeneMedicine(GM) is a clinical stage biopharmaceutical company focused on developing next-generation viral immunotherapies, aiming to transform the therapeutic outcomes for cancer patients. Using our proprietary adenovirus platform, we're developing several pipeline products that can be intratumorally and intravenously administered to selectively attack and eradicate tumor cells as well as potently stimulating multiple arms of antitumor immune response. Our viral immunotherapy has proven effective as both a standalone therapy and in combination with current standard of care, including immune checkpoint inhibitors (ICI). Intratumoral administration of GM oncolytic adenovirus offers several advantages over competitor products;(1) higher level of virus accumulation and localization in tumor tissues and (2) lower off-target systemic exposure, ultimately exerting potent therapeutic effect with minimal systemic toxicity. Our pipeline can effectively treat wide range of tumor types, including breast cancers (triple-negative and hormone receptor-positive), prostate cancer, melanoma, and non-melanoma skin cancer, desmoplastic cancers (like pancreatic cancer), and injectable visceral tumors that have spread to the liver, such as metastases from colorectal and lung cancer. To treat metastatic and recurrent cancers in late-stage cancer patients, we've developed systemic delivery platform for oncolytic viruses that avoids rapid blood clearance and inactivation by the immune system and various blood components. GM’s potent multi-armed oncolytic viral platform GM-OAd mediated oncolysis results in immunogenic cell death to trigger robust antitumor immune activation and memory formation to ensure long-term therapeutic benefit against cancer. GM has a highly scalable, low cost manufacturable platform offering highly versatile, innovative treatment options for patients with advanced or metastatic tumors.
11 to 50 staff
Glory Biotech Corp
Glory Biotechnologies Corp. is an expert innovative research and development company dedicated to the development of new diagnostics systems for the diagnosis of incurable diseases and providing complete solutions for the Biotechnology Industry. Glory Biotechnologies Corp. was established as a biotech venture in Seoul, 2014. Since its establishment, the company has kept on gaining ground in conjunction with different research projects such as KOICA (CTS Program) by employing aspiring experts and ambitious professionals to develop diagnostic instruments, providing the LIMS, Lab automation, Data management and Biobanking, Molecular biology reagents and solutions for Pharmaceutical industries. Our slogan “For giving Better Life” is a clear indication of our establishing mission, and our aim is to discover, create, and effectively showcase or change to highlight new restorative applicant substances through persistent innovative work, thereby contributing to the welfare of humanity. We have kept on building a solid patent portfolio by gathering significant intellectual property, which is essential in the inventive economy. The development of new diagnostic systems is a high-hazard business that requires huge time and venture. It is not an easy job for extraordinary researchers and companies to develop a new diagnostic instrument all alone. To accomplish the demand in this era of specialized union and redid prescription, Glory Biotechnologies Corp. kept on extending its joint research and innovation, improvement by creating networks with driving domestic bio-innovation organizations international biotechnology based company. Glory Biotechnologies Corp. will continually endeavor to grow new diagnostic instrument that is very much perceived in the worldwide medical instrument market. We will also continue to further strengthen our R&D capabilities as a global leader. Kindly, give your support to Glory Biotechnologies Corp. of a developing invisible champion.
11 to 50 staff
Greengene
Our unique and proprietary platform technology - Organelle(Chloroplast and Mitochondria) gene editing - enables us to edit RuBisCo, a key enzyme in photosynthesis and the most abundant protein in the world. We believe that our research and vision can lead to the ultimate key solution for climate crisis and food scarcity.
11 to 50 staff
Imbdx
IMBdx is a precision oncology company committed to advancing safe and accurate cancer diagnosis, monitoring, and screening. We have developed a minimally-invasive liquid biopsy technology that detects cancer and monitors its progression with just a single blood draw. Our AlphaLiquid® test provides comprehensive genomic profiling (CGP) of tumors, identifying key mutations and offering personalized treatment options, including matching therapies and relevant clinical trial opportunities. In addition to AlphaLiquid®, we offer CancerDetectTM, a minimal residual disease (MRD) test that detects trace amounts of cancer cells remaining after treatment, allowing for early relapse detection. We also provide CancerFindTM, a multi-cancer early detection (MCED) test that screens for multiple types of cancer at once, even in asymptomatic patients, enabling earlier and more effective intervention. Since beginning our research in 2014, our goal has been to make cancer diagnosis more accessible and affordable for patients worldwide. For more information, please visit or contact us at support@imbdx.com.
51 to 200 staff
